Figure 4.

Decision maker and expectations regarding new DMT. (a) Patients’ assessment of decision maker for the switch. (b) Physicians’ expectations regarding new DMT. (c) Patients’ expectations regarding new DMT.

^aData were recorded using patient questionnaires. Multiple answers per patient were possible.

^bData were recorded using physician questionnaires. Up to three answers were possible. Answer options: relevance of drug characteristics with regard to prevention of relapses, prevention of new lesions, effects on progression of disability, good tolerability, less extensive pharmacovigilance monitoring, convenient application form, costs.

^cData were recorded using patient questionnaires. Up to two answers were possible. Answer options: relevance of drug characteristics with regard to good effectiveness, effects on progression of disability, good tolerability, convenient application form.

DMT, disease modifying therapy.